Ironwood Pharmaceuticals Inc (IRWD) · Oct 16, 2026 · Exec change

Ironwood CEO change keeps turnaround in-house as McCourt retires

CEO succession — Internal promotion; effective January 1, 2027

Ironwood’s CEO change promotes commercial chief Tammi Gaskins while Tom McCourt retires, preserving continuity through the LINZESS and apraglutide transition.

Ironwood is in a rebuilding phase: it is pushing a LINZESS commercial turnaround while funding the confirmatory STARS-2 trial for apraglutide, its main late-stage pipeline opportunity. In August, the company had raised 2026 guidance, with LINZESS U.S. sales expected at $1.15–$1.20 billion, while STARS-2 was actively recruiting.

This is an orderly succession, not a strategy reset. Ironwood is promoting Chief Commercial Officer Tammi Gaskins to CEO effective January 1, 2027. Her background maps directly onto the two operating priorities investors already know: commercial execution around LINZESS and development of apraglutide. The filing says she helped drive the LINZESS turnaround and led commercial development efforts for apraglutide, which makes the choice look like continuity with a new operator rather than a forced change.

McCourt’s departure is softened by continued board involvement. He is retiring after 17 years with Ironwood but will remain a director and is expected to consult for the company after the transition. 〔0〕 That reduces the risk of an abrupt loss of institutional knowledge, although it also means the handoff will be judged on whether Gaskins can move from commercial leadership to full-company leadership without slowing the apraglutide or LINZESS execution.

The compensation package is meaningful but not the central signal. Gaskins will receive a $775,000 base salary, a 75% target bonus, and approximately $4 million of target RSU and PSU grants. The package establishes substantial retention and performance incentives, but the filing does not indicate a change in capital allocation, pipeline priorities, or operating guidance.

Bottom line: Ironwood is replacing its CEO with an internal executive closely tied to the current turnaround, making this more a continuity event than a disruption. It modestly improves leadership clarity, but the business story still depends on LINZESS execution and STARS-2 progress rather than the succession itself.

What to watch next

CEO transition effective January 1, 2027

Original filing on SEC EDGAR

More Ironwood Pharmaceuticals Inc news

Ironwood CEO change keeps turnaround in-house as McCourt retires | IRWD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.